A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of Thorium-227 Labeled Antibody-chelator Conjugate BAY2701439, in Participants With Advanced HER2-expressing Tumors

  • End date
    Jul 28, 2028
  • participants needed
  • sponsor
Updated on 18 September 2022


In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor Receptor 2) and cannot be cured by currently available treatment options. The study will include patients with HER2 expressing breast, gastric (stomach) or gastroesophageal (stomach and esophagus) cancer, as well as other cancers that have HER2. Researchers want to find the best dose of BAY2701439 for patients and look at the way the body absorbs, distributes and excretes the drug.

The study drug is a type of therapy called a 'targeted alpha therapy' which uses an antibody to deliver a radioactive particle to cancer cells. BAY2701439 contains thorium-227 which emits radiation (a lot of energy that moves from one place to another with damaging effects). The thorium-227 in the drug is attached to an 'antibody' (large protein) that specifically binds to HER2 on the cancer cells and will emit its radiation in the form of alpha particles. The alpha particles are expected to damage the tumor cells and cause them to die, but spare surrounding tissue as alpha particles travel only very short distances in the body. This is the first study in humans for drug BAY2701439. Patients participating in this study will receive the drug by injection every 6 weeks a maximum 6 times. Observation after treatment last up to 3 years.

Condition Cancers With HER2 Expression
Treatment BAY2701439, BAY2701438
Clinical Study IdentifierNCT04147819
Last Modified on18 September 2022


Yes No Not Sure

Inclusion Criteria

Male or female participants at least 18 years of age on the day of signing informed consent
Participants must meet the study phase-specific disease requirements
Dose escalation
Pathologically documented, HER2-expressing (IHC3+, 2+, or 1+ and/or ISH+), unresectable
locally advanced or metastatic gastric, gastroesophageal, or breast cancer that has
relapsed after standard treatment options, or for which no standard treatment is available
Participants with gastric or gastroesophageal cancer must not have had prior definitive
radiotherapy. Participants in the dose escalation cohorts must have evaluable disease by
RECIST 1.1, assessed by local imaging
Dose expansion: Group A: Pathologically documented unresectable, locally advanced or
metastatic breast cancer with HER2 overexpression or amplification (IHC3+ or IHC2+/ISH+)
that has relapsed that has relapsed after standard treatment options, or for which no
Group B: Pathologically documented unresectable locally advanced or metastatic breast
standard treatment is available
cancer with HER2 low expression (IHC2+/ISH-, IHC1+/ISH-, or IHC1+/ISH untested) that has
relapsed after standard treatment options, or for which no standard treatment is available
Group C: Pathologically documented, unresectable locally advanced or metastatic carcinomas
other than breast cancer with HER2 overexpression or amplification/mutation (IHC3+ or
IHC2+/ISH+), that has relapsed after standard treatment options or for which no standard
treatment is available
Participants in the dose expansion cohorts must have measurable disease by RECIST 1.1
assessed by local imaging
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
Availability of fresh or archival tumor samples - archival tumor samples obtained
Life expectancy of at least 6 months, as estimated by the Investigator
after disease progression on the most recent anti-cancer treatment may be accepted
those obtained prior to the last anti-cancer treatment may be accepted, upon agreement
between the Sponsor and the Investigator
Adequate bone marrow, hepatic, and renal function, as assessed by the following
laboratory requirements, to be conducted within 28 days before start of BAY2701439
Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count (ANC) ≥ 1500/mm3
Platelet count ≥ 100,000/mm3
Male and/or female who meet the requirements for contraception and breastfeeding as
Total bilirubin ≤ 1.5 X the upper limit of normal (ULN), except if confirmed
history of Gilbert's disease
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ˂ 2.5 x ULN
(≤ 5 x ULN for participants with liver involvement)
Participants on a stable dose of anti-coagulation therapy will be allowed to
participate if they have no sign of bleeding or clotting, and Prothrombin
time/International normalized ratio (PT/INR) and aPTT test results are compatible
with the acceptable benefit-risk ratio at the Investigator's discretion
Serum creatinine ≤ 1.5 x ULN and glomerular filtration rate (GFR)≥ 45 mL/min/1.73
m2, according to the Modified Diet in Renal Disease (MDRD)abbreviated formula
A negative serum pregnancy test in women of childbearing potential (WOCBP) performed
within 7 days before the start of BAY2701439 administration. Women and men of
reproductive potential must agree to use highly effective methods of contraception
when sexually active, during the time period between signing the informed consent form
until at least 6 months after the last administration of BAY2701439
Male participants: A male participant must agree to use highly effective contraception
during the intervention period and for at least 6 months after intervention and refrain
from donating sperm during this period
Female participants: A female participant is eligible to participate if she is not pregnant
(confirmed by a negative serum pregnancy test within 7 days of first study treatment), not
breastfeeding, or is not a woman of childbearing potential
Women of childbearing potential (WOCBP) must agree to use highly effective contraception
during the intervention period and for at least 6 months after the last dose of study
Contraceptive use by men or women should be consistent with local regulations regarding the
methods of contraception for those participating in clinical studies
Capable of giving signed informed consent which includes compliance with the requirements
and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria

Impaired cardiac function or clinically significant cardiac disease (i.e. congestive
heart failure (CHF) New York Heart Association (NYHA) Class II, III or IV)
Left ventricular ejection fraction (LVEF) < 50% (as measured at screening by
History or concurrent condition of interstitial lung disease/pneumonitis or severely
impaired pulmonary function
Participants known to be affected by genetic defects linked to radiation
hypersensitivity, such as ataxia-telangiectasia (A-T; Online Mendelian Inheritance in
Man [OMIM] #208900) and A-T-like disorder (meiotic recombination 11 homolog [MRE11])
Nijmegen breakage syndrome (OMIM #251260) and Nijmegen breakage Syndrome-like disorder
(RAD50), Fanconi anemia (OMIM #227650), DNA ligase IV deficiency (OMIM #606593)
RIDDLE syndrome (RNF168), radiosensitive severe combined immunodeficiency (RS-SCID)
DNA-PK radiosensitive combined immunodeficiency (DNA-PK-RS-SCID), Cornelia de Lange
History of Myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukemia
(t-AML) or with features suggestive of MDS/AML
Infections of Common terminology criteria for adverse events (CTCAE) version 5.0 Grade
not responding to therapy or active clinically serious infections of CTCAE Grade >2
History of hypersensitivity or severe infusion related reaction to any
Trastuzumab-containing drug (e.g. trastuzumab, T-DM1) or any other ingredients
contained in BAY2701439
Chemotherapy, experimental cancer therapy, biologic therapy or immunotherapy within 4
weeks before start of BAY2701439 administration. Start of study treatment is allowed
in shorter timeframes provided 5 half-lives of the prior drug(s) have elapsed before
the start of BAY2701439 administration. Previous high-dose chemotherapy needing
hematopoietic-stem-cell-rescue is prohibited
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note